According to OG Analysis, the global Cholesterol Test Market is projected to grow from USD 13.3 billion in 2026 to USD 25.1 billion by 2034, registering a CAGR of 8.26%. The report covers products, applications, technologies, end users and distribution channels across five regions.
Full report: https://www.oganalysis.com/industry-reports/cholesterol-test-market
Market Overview
Cholesterol testing measures blood lipids to support cardiovascular risk assessment and monitoring of lipid-lowering therapy. Routine lipid panels report total cholesterol, HDL cholesterol and triglycerides, with LDL cholesterol calculated or measured directly depending on the test pathway. Laboratories use automated chemistry systems, while validated point-of-care platforms support testing closer to patients. Demand spans preventive screening, hospital care and management of people with diabetes or other cardiovascular risk factors.
Market development centers on compact analyzers, laboratory automation and connected reporting that help providers manage volumes and turnaround times. Home collection supports laboratory testing without a conventional collection visit, while self-testing requires devices designed for the intended user. Advanced lipid markers can complement standard panels when clinically appropriate. Suppliers compete through assay performance, instrument placement, reagent supply and technical support. Sample quality, quality assurance and accessible follow-up remain important across service models.
Key Market Insights
- Routine lipid panels combine cholesterol measurements and triglyceride testing to inform risk assessment and treatment monitoring.
- Point-of-care systems can provide results during a clinic or community visit, supporting timely discussion with healthcare professionals.
- Laboratory automation supports throughput and standardized workflows, with calibration and quality control essential to dependable results.
- Home collection and self-testing offer different service models, sample requirements, test menus and intended users.
- Assay performance and quality assurance help providers interpret results consistently across testing locations and follow-up visits.
- Lipoprotein(a) and apolipoprotein B testing can supplement traditional lipid panels for more detailed cardiovascular risk assessment.
Market Dynamics
- Driver: Preventive screening and ongoing monitoring sustain demand for routine lipid assessment across healthcare settings.
- Driver: Diabetes management and cardiovascular care pathways incorporate cholesterol testing to support broader risk assessment.
- Opportunity: Pharmacy and community testing services can expand access when linked with interpretation and appropriate follow-up.
- Opportunity: Validated capillary sampling and home collection can broaden collection options for laboratory testing.
- Restraint: Decentralized services need consistent sample handling, operator training and quality control to deliver reliable results.
- Restraint: Testing costs, reimbursement arrangements and access to follow-up care can influence uptake across patient groups.
- Opportunity: Automated analyzers and digital reporting can improve workflow efficiency and support continuity of monitoring.
Browse for More Information
https://www.oganalysis.com/industry-reports/cholesterol-test-market
Market Segmentation
By Product Type: Reagent Kits, Analyzers and Others. By Application: Cardiovascular Diseases, Diabetes Management and Preventive Healthcare. By End User: Hospitals, Diagnostic Laboratories and Home Care Settings.
By Technology: Point-of-Care Testing and Laboratory Testing. By Distribution Channel: Online and Offline. These segments capture differences in equipment, purchasing routes and delivery settings; device suitability depends on its intended use.
Regional Insights
- North America: U.S. laboratory networks and updated dyslipidemia guidance support screening and treatment monitoring, with advanced markers complementing routine cholesterol assessment.
- Europe: England’s planned pharmacy pilot illustrates interest in community cholesterol checks linked with consultation, alongside established laboratory services.
- Asia-Pacific: Singapore’s Healthier SG screening programme includes blood cholesterol assessment through participating primary care providers, integrating testing with preventive health services.
- Middle East & Africa: South Africa’s Clicks Clinics offers cholesterol and lipogram testing within wellness services, illustrating access through retail health clinics.
- South & Central America: Brazil’s Fleury provides total and fractionated cholesterol testing through its laboratory services for routine lipid assessment.
Competitive Landscape
Competition spans instrument and reagent manufacturers, point-of-care specialists and clinical laboratory networks. Buyers assess analytical performance, throughput, connectivity and ongoing support alongside cost. Service differentiation depends on collection convenience, reliable turnaround and clear reporting, while partnerships and acquisitions extend portfolios and geographic reach.
Selected market participants include Roche, Abbott, Siemens Healthineers, Danaher (Beckman Coulter Diagnostics), QuidelOrtho, Randox Laboratories, HORIBA, Mindray (DiaSys), SEKISUI Diagnostics, Sinocare (PTS Diagnostics), Quest Diagnostics and Labcorp.
Recent Industry Developments
- October 2026: Labcorp and Thrive Global launched the Thrive5 Health Test via Labcorp OnDemand, pairing apolipoprotein B and other cardiometabolic measurements with educational resources. Source
- August 2026: NHS England reported plans for around 100 pharmacies to offer seven-minute cholesterol checks during an autumn pilot, with pharmacist consultations supporting interpretation and follow-up. Source
- July 2026: Siemens Healthineers launched CE-marked capillary-testing capabilities for Atellica analyzers, including lipid-panel assays, extending core laboratory testing to validated finger-prick and heel-stick samples. Source
- April 2026: Sysmex completed its acquisition of JEOL’s clinical chemistry business, establishing Sysmex BioMajesty and adding analyzer platforms supporting cholesterol and other routine biochemical tests. Source
- March 2026: ACC/AHA issued updated dyslipidemia guidance recommending lipoprotein(a) measurement at least once in adulthood and selective apolipoprotein B testing to refine cardiovascular risk assessment. Source
- January 2026: Truvian announced FDA clearance for total cholesterol and triglyceride testing on TruVerus, with calculated VLDL results, expanding its benchtop test menu for venous whole blood samples. Source
- January 2025: Roche announced FDA clearance of its Tina-quant Lipoprotein(a) Gen.2 Molarity assay, reporting lipoprotein(a) in nanomoles per liter to support cardiovascular risk assessment. Source